ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Characterization of Human Plasma Cell Proteasome Adaptations to Proteasome Inhibitor Therapy: A Precision Medicine Approach to Overcome Drug Resistance in Desensitization.

J. Driscoll,1 S. Tremblay,1 P. Brailey,1 A. Girnita,1 R. Alloway,1 B. Aronow,2 H. Singh,2 E. Woodle.2

1U of Cincinnati, Cincinnati, OH
2Cincinnati Children's, Cincinnati, OH

Meeting: 2017 American Transplant Congress

Abstract number: 109

Keywords: B cells, Genomics, HLA antibodies, Kidney transplantation

Session Information

Date: Sunday, April 30, 2017

Session Name: Concurrent Session: Clinical Science: Kidney Immunosuppression: Desensitization

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:42pm-5:54pm

Location: E354b

Related Abstracts
  • RNAseq Transcriptome Analysis of Bone Marrow CD138+ Plasma Cell Responses to Carfilzomib Monotherapy Desensitization.
  • A Novel 3-Dimensional Culture System Enables In Vitro Study of Human Bone Marrow Plasma Cells.

Purpose: Bone marrow niche-resident plasma cells (BMNRPCs) exhibit variable sensitivity to proteasome inhibitor (PI) therapy. Here, we characterized alterations in the gene and protein expression of human PC proteasome components that may mediate resistance to PI desensitization therapy.

Methods: HLA-sensitized transplant candidates received CFZ (20, 27, 36 mg/m2) with BM aspirates performed before and after CFZ. CD138+ BMNRPCs were isolated to >98% purity and total RNA analyzed on Ilumina TruSeq NGS platform (30 million reads/sample with paired end 75 bp sequencing). Strongly and differentially expressed gene sets were clustered and evaluated using enrichment and prior knowledge-based network and interactions analyses with ToppGene Suite.

Results: CFZ treatment significantly reduced BMNRPCs by ~70% as well as immunodominant antibody levels in HLA-sensitized patients. RNA-Seq analysis revealed that PSMB8, PSMB9, PSMB10, genes that encode the immunoproteasome (a structural variant of the constitutive proteasome with distinct catalytic activities and inhibitor sensitivities) were significantly upregulated in BMNRPCs that survived CFZ (Fig. 1A). In vitro evaluation of proteasome catalytic activities in BMRPCs revealed reduced chymotryptic-like inhibition by CFZ, bortezomib and ixazomib, but increased inhibition with an immunoproteasome-specific inhibitor, ONX-0914 (Fig. 1B). Western blotting indicated that immunoproteasome gene products were incorporated into high proteasome complexes and altered the substrate activities.

Conclusions: We demonstrate a shift toward immunoproteasome-specific proteolysis that mediates relative resistance to inhibitors of constitutive proteasomes in surviving BMNRPCs. Precision medicine may reveal novel strategies to overcome drug resistance, e.g., sequential therapy with a constitutive and immunoproteasome-selective inhibitor, that may enhance PC depletional therapy.

CITATION INFORMATION: Driscoll J, Tremblay S, Brailey P, Girnita A, Alloway R, Aronow B, Singh H, Woodle E. Characterization of Human Plasma Cell Proteasome Adaptations to Proteasome Inhibitor Therapy: A Precision Medicine Approach to Overcome Drug Resistance in Desensitization. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Driscoll J, Tremblay S, Brailey P, Girnita A, Alloway R, Aronow B, Singh H, Woodle E. Characterization of Human Plasma Cell Proteasome Adaptations to Proteasome Inhibitor Therapy: A Precision Medicine Approach to Overcome Drug Resistance in Desensitization. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/characterization-of-human-plasma-cell-proteasome-adaptations-to-proteasome-inhibitor-therapy-a-precision-medicine-approach-to-overcome-drug-resistance-in-desensitization/. Accessed March 8, 2021.

« Back to 2017 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Home
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Search
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Home
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.